搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按相关度排序
按时间排序
1 天
Jim Cramer’s Take on Eli Lilly and Company (LLY): Bold Predictions for the Future
We recently compiled a list of the Jim Cramer’s Bold Predictions About These 10 Healthcare Stocks. In this article, we are ...
4 天
Is Eli Lilly Stock a Buy?
Ozempic has gotten most of the name recognition associated with weight-loss drugs, it's not the only drug in this category ...
来自MSN
2 天
Is Eli Lilly Stock a Buy, Sell, or Hold for 2025?
Investing in rapidly expanding biotech stocks can be a worthwhile long-term investment. Just one successful drug or device ...
24/7 Wall St
2 天
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) e estimate Rivian’s stock price to be $140.00 per share. Our estimated stock ...
1 天
on MSN
Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More.
Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...
2 天
on MSN
Is Eli Lilly and Company (LLY) the Best Pharma Dividend Stock to Buy In 2024?
We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...
7 天
Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.
Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...
8 小时
Vivienne Scarpellini named 2025 Lawrence County Lilly scholar
The scholarship will pay for 4 years of tuition, fees and books at an Indiana public or private nonprofit college or ...
5 天
on MSN
Eli Lilly to end 2024 among best in Big Pharma; Novo among worst
Eli Lilly (LLY) emerges among the top performers in Big Pharma in 2024 with obesity drug success, while Novo Nordisk (NVO) ...
The Financial Express
2 天
Eli Lilly’s Zepbound holds potential to dominate obesity market
Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...
13 天
Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...
2 天
on MSN
Eli Lilly's Zepbound Drug Likely To Dominate Global Obesity Market: Report
New Delhi: Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈